Evidence map›Paper›PMID 31794074›Full record

ArticleThe British journal of dermatology2020

Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP).

L M Howells, J R Chalmers, S Gran, A Ahmed, C Apfelbacher, T Burton, L Howie, S Lawton, M J Ridd, N K Rogers and 4 more

Open access · hybridAbstract read
In one paragraph

Article in The British journal of dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2024
    Pooled it
  2. Pooled it
  3. Topical anti-inflammatory treatments for eczema: network meta-analysis.The Cochrane database of systematic reviews · 2024
    Pooled it
  4. Phototherapy for atopic eczema.The Cochrane database of systematic reviews · 2021
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Atopic dermatitis.Nature reviews. Disease primers · 2026
    Review
  13. Article
  14. Defining "Flares" in Atopic Dermatitis: A Narrative Review.American journal of clinical dermatology · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 4 countries.

L M HowellsCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.ORCID 0000-0003-4157-7394
J R ChalmersCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.ORCID 0000-0002-2281-7367
S GranCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.ORCID 0000-0002-2443-5100
A AhmedPatient representative, Nottingham, UK.
C ApfelbacherDepartment of Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.ORCID 0000-0003-3805-8219
T BurtonPatient representative, Nottingham, UK.
L HowiePatient representative, Brisbane, Australia.
S LawtonRotherham NHS Foundation Trust, Rotherham, UK.
M J RiddDepartment of Population Health Science, University of Bristol, Bristol, UK.ORCID 0000-0002-7954-8823
N K RogersCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.ORCID 0000-0001-9076-129X
A V SearsSt John's Institute of Dermatology and Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
P SpulsDepartment of Dermatology, Amsterdam University Medical Centers, Academic Medical Center, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, the Netherlands.
L von KobyletzkiCentre for Clinical Research, Malmö, Lund University, Sweden.
K S ThomasCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.ORCID 0000-0001-7785-7465
University of Nottingham · GBAmsterdam UMC Location University of Amsterdam · NLKing's College London · GBLund University · SEThe Rotherham NHS Foundation Trust · GBUniversity of Bristol · GBUniversity of Regensburg · DE

Funding

British Skin Foundation 8016
6 · The paper itself

Abstract

backgroundEczema control has been identified as an important outcome by key stakeholders in eczema research (including patients, carers, healthcare professionals and researchers) but no validated instruments for the domain have been identified.

objectivesTo develop a measurement instrument to capture a patient's perspective of eczema control that is suitable for use in eczema clinical trials.

methodsBest practice for the development of a patient-reported outcome was followed. A mixed-methods approach was used to develop and refine a conceptual framework, generate, refine and select items and to test the distribution and construct validity of the final scale. The mixed-methods approach involved expert panel meetings (including patient representatives, healthcare professionals and methodologists), and data collection using a focus group, cognitive interviews and an online survey with people with eczema and caregivers. Multivariable linear regression was used in the item selection process.

resultsFourteen expert panel members co-produced the instrument, with input from people with eczema and caregivers via a focus group (n = 6), cognitive interviews (n = 13) and an online survey (n = 330). The resulting instrument, Recap of atopic eczema (RECAP), is a seven-item questionnaire that captures eczema control via self or caregiver report. The development process aimed to ensure good content validity and feasibility. Initial testing suggested no floor or ceiling effects and good construct validity. Hypothesized correlation with the Patient-Oriented Eczema Measure was confirmed [r(258) = 0·83, P < 0·001].

conclusionsRECAP has the potential to improve reporting of eczema control in research and clinical practice. Further exploration of measurement properties is required. Linked Comment: Pattinson and Bundy. Br J Dermatol 2020; 183:418-419. What's already known about this topic? Eczema control has been identified as an important outcome by key stakeholders in eczema research (including patients, carers, healthcare professionals and researchers). Qualitative studies suggest eczema control is a multifaceted and individual experience and no instrument has been identified that captures eczema control in this way. What does this study add? We have developed Recap of atopic eczema (RECAP), a seven-item questionnaire to capture the experience of eczema control in all ages and eczema severities; there are two versions: a self-reported version for adults and older children with eczema, and a caregiver-reported version for younger children with eczema. Designed with input from people with eczema, caregivers and healthcare professionals to ensure good content validity. Initial testing of score distributions and construct validity suggests good measurement properties. What are the clinical implications of the work? The RECAP instrument is appropriate and feasible for measuring eczema control in clinical trials and may also be useful in routine practice.

Indexed as

Dermatitis, AtopicEczemaAdolescentAdultCaregiversChildHumansPatient Reported Outcome MeasuresSurveys and Questionnaires

Identifiers

PMID31794074
PMCPMC7496132
OpenAlexW2993210980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.